SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...
PR Newswire SAN RAFAEL, Calif., April 2, 2025 Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceut ...
Revenue in the third quarter fell 9% to $11.3 billion, while earnings per share tumbled 30% from $0.77 to $0.54. Gross margin ...
12h
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
Newly decoded correspondence reveals that Mary, Queen of Scots was involved in various plots to free her from her English imprisonment.
The requirement of obeying even erroneous court orders on appeal (absent a stay) is based on the authority of the trial court ...
"A waterproof Gore-Tex upper, an all-terrain outsole, and reflective details help you comfortably take on the elements." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback